The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
In this study the researchers will be enrolling patients who are failing their current
antiretroviral regimen who also have resistance to 3TC or FTC. Patients will have their
current antiretroviral regimen changed based on resistance testing and also be randomly
assigned to either include, or not include 3TC/FTC in this new regimen. The purpose of the
research is to investigate whether the change in therapy results in a decrease in the amount
of virus particles and an increase in the CD4 cell count. In addition the researchers are
investigating the relationship between the existence of resistance and the rate of decrease
in viral load, and also to determine if continuing 3TC/FTC (despite being resistant to the
medications) has any effect on the rate of decrease of viral load, or effect on CD4 counts.
Phase:
N/A
Details
Lead Sponsor:
Stanford University
Collaborators:
Santa Clara Valley Health & Hospital System University of California, Davis